Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 11 symbols : GILD save search
Second Genome Presents Preclinical Data Highlighting Potential Therapeutic Implications of Altered Gut Microbiome and Metabolites in Autism Spectrum Disorder Model and Parkinson's Disease at The Society for Neuroscience Annual Meeting
Published: 2021-11-11 (Crawled : 14:15) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.8%
H: 0.73%
C: 0.64%
disease potential parkinson preclinical pre-clinical
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
Published: 2021-11-11 (Crawled : 01:00) - prnewswire.com
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.8%
H: 0.73%
C: 0.64%
phase 2 china cancer phase 2b breast cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.